Literature DB >> 2880637

Stimulation of both D1 and D2 dopamine receptors appears necessary for full expression of postsynaptic effects of dopamine agonists: a neurophysiological study.

J H Carlson, D A Bergstrom, J R Walters.   

Abstract

The abilities of 4 dopamine agonists to inhibit the tonic single unit activity of substantia nigra dopamine neurons and stimulate tonic activity of globus pallidus neurons were compared to study the agonists' effects on pre- and postsynaptic dopamine receptors, respectively. The agonists studied were apomorphine and pergolide, which interact with both D1 and D2 receptors, and the selective D2 agonists quinpirole and RU 24926. Drugs were administered systemically. The 4 dopamine agonists were equipotent and equiefficacious at inhibiting the firing rates of dopamine neurons. In contrast, their effects on pallidal cells were not identical; apomorphine and pergolide induced significantly greater increases in pallidal cell activity than did quinpirole and RU 24926. In addition, pretreatment with a small dose of quinpirole did not attenuate the excitatory effect of apomorphine on globus pallidus cell activity, as low doses of apomorphine have previously been shown to do. Possible mechanisms underlying the differences in efficacy between the non-selective and D2 selective dopamine agonists in the globus pallidus were investigated. Coadministering quinpirole with apomorphine did not significantly attenuate the effect of apomorphine, suggesting that quinpirole is not a partial agonist at postsynaptic dopamine receptors. In addition, prazosin pretreatment did not attenuate the stimulatory effect of pergolide on firing rates of pallidal cells, indicating that the greater efficacy of the non-selective agonists was not due to concurrent stimulation of alpha 1 adrenergic receptors and dopamine receptors. However, the effect of quinpirole on pallidal cell activity was significantly potentiated by pretreatment with the D1 agonist RS-SKF 38393 but not its inactive enantiomer S-SKF 38393. These results suggest that concurrent D1 and D2 receptor stimulation may be necessary for the full expression of postsynaptic receptor-mediated effects of dopamine and dopamine agonists in the basal ganglia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2880637     DOI: 10.1016/0006-8993(87)90619-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  28 in total

1.  A simple biological way to screen dopaminergic agonists.

Authors:  F A de Azeredo; M F Ribeiro
Journal:  Metab Brain Dis       Date:  1992-12       Impact factor: 3.584

Review 2.  The external globus pallidus: progress and perspectives.

Authors:  Daniel J Hegeman; Ellie S Hong; Vivian M Hernández; C Savio Chan
Journal:  Eur J Neurosci       Date:  2016-03-28       Impact factor: 3.386

3.  Effects of selective D1 and D2 dopamine antagonists on the development of behavioral sensitization to apomorphine.

Authors:  B A Mattingly; J K Rowlett; J T Graff; B J Hatton
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  Presynaptic actions of D2-like receptors in the rat cortico-striato-globus pallidus disynaptic connection in vitro.

Authors:  Katsushige Watanabe; Takako Kita; Hitoshi Kita
Journal:  J Neurophysiol       Date:  2008-12-10       Impact factor: 2.714

Review 5.  Striatal dopamine in motor activation and reward-mediated learning: steps towards a unifying model.

Authors:  J Wickens
Journal:  J Neural Transm Gen Sect       Date:  1990

6.  Behavioural responses to the selective D1-dopamine receptor agonist R-SK&F 38393 and the selective D2-agonist RU 24213 in young compared with aged rats.

Authors:  A G Molloy; J L Waddington
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

7.  Effects of D2 dopamine receptor blockade with raclopride on intracranial self-stimulation and food-reinforced operant behaviour.

Authors:  S Nakajima; J D Baker
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 8.  Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.

Authors:  R G Fariello
Journal:  Drugs       Date:  1998       Impact factor: 9.546

9.  Enhancement by a single dose of reserpine (plus alpha methyl-p-tyrosine) of the central stimulatory effects evoked by dopamine D-1 and D-2 agonists in the mouse.

Authors:  S B Ross; D M Jackson; E M Wallis; S R Edwards
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-05       Impact factor: 3.000

10.  Role of excitatory amino acids in the direct and indirect presynaptic regulation of dopamine release from nerve terminals of nigrostriatal dopaminergic neurons.

Authors:  A Cheramy; M L Kemel; C Gauchy; J M Desce; T Galli; L Barbeito; J Glowinski
Journal:  Amino Acids       Date:  1991-10       Impact factor: 3.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.